Hepatitis C virus accounts for 40% of cases with end stage cirrhosis, 60% of cases with hepatocellular carcinoma (HCC). It is estimated that 15–40% of chronic hepatitis B patients develop severe liver complications such as cirrhosis or HCC in their lifetimes, contributing to more than 1 million deaths every year.Novel non-invasive methods might provide preliminary information with good diagnostic accuracy for further selection of patients at risk for progressive liver disease rather than liver biopsy.Biochemical markers of liver fibrosis such as fibronectin, pseudocholinesterase and prothrombin concentration have been proposed as indicators of change from chronic hepatitis to cirrhosis. The aim of this study is evaluating fibronectin, pseudo-cholinesterase and prothrombin concentration when combined in a specific equation, to discriminate between advanced fibrosis and cirrhosis and, to predict HCC in liver cirrhosis.Methods: Commercially available ELISA assay were used to study circulating levels of fibronectin in plasma, quantitative kinetic assay for pseudocholinesterase in serum and prothrombin time in seconds was plotted on calibration curve and the result was read in % to determine prothrombin activity. The three parameters were integrated in a specific equation. All patients with chronic hepatitis C or hepatitis B (n=70). 20 patients with fibrosis grade F3, 25 patients with grade F4 and 25 patients with grade F4 and HCC. 10 individuals as healthy control group. Hepatic histology was evaluated using METAVIR scoring system.Results: it was found that the equation significantly discriminates between fibrosis and cirrhosis but cannot discriminate between cirrhosis and HCC. Pseudocholinesterase was also found to significantly discriminate between fibrosis and cirrhosis and between cirrhosis and HCC. Fibronectin showed no value to discriminate neither between fibrosis and cirrhosis nor between cirrhosis and HCC.Conclusion: The equation acts as a good non-invasive method to discriminate between chronic active hepatitis and cirrhosis. Serum pseudocholinesterase alone can act as a good marker for the follow up of advanced liver fibrosis patients and can predict HCC in cirrhotic patients. Fibronectin alone is not a reliable test in liver disease.